Key Takeaways
- • Operational execution, not financial engineering, ranked as the primary driver of healthcare PE performance in 2026, according to a live poll of conference participants at HPE Miami March 4–5, signaling a structural shift in how PE firms create value in healthcare assets.
- • More than 2,000 healthcare founders, investors, advisers, and leaders convened at the McDermott Will & Schulte HPE Miami 2026 conference to assess structural and policy forces reshaping the health and life sciences investment landscape, with McKinsey serving as the official knowledge partner.
- • PE firms are expected to develop deep operational capabilities and specialized expertise within portfolio companies rather than relying primarily on high-level strategic guidance from the boardroom, reflecting a move away from traditional acquisition-and-advise models.
- • Compliance and quality remain central to value creation in healthcare PE transactions, with panelists underscoring these factors as essential components of deal structuring and portfolio company performance.
- • Talent acquisition, technology innovation, and competition from global pharmaceutical companies emerged as critical external factors shaping deal flow and investment strategy for PE buyers and sellers positioning transactions through 2026.
Summary
The McDermott Will & Schulte HPE Miami 2026 conference, held March 4–5 in Miami Beach, Florida, drew over 2,000 healthcare industry participants—including founders, investors, advisers, and sector leaders—to examine the structural and policy forces reshaping health and life sciences investment. McKinsey & Company served as the official knowledge partner for the event, synthesizing key trends and considerations emerging from panel discussions.
A defining theme from the conference centers on a fundamental shift in how private equity firms create value in healthcare. A live poll conducted during HPE Miami panels revealed that operational execution ranked as the most significant determinant of near-term investment performance, surpassing financial engineering as the primary value driver. This finding reflects a broader evolution away from the traditional PE model of acquiring strong healthcare businesses and relying primarily on strategic boardroom guidance. Instead, institutional investors and PE sponsors increasingly expect firms to possess deep operational capabilities and specialized expertise embedded within portfolio companies, enabling active support for operational improvements rather than passive strategic oversight.
Compliance and quality assurance remain central to value creation in healthcare PE transactions, with panelists emphasizing these factors as non-negotiable components of deal structuring and post-acquisition performance. Panelists also identified talent retention and recruitment as increasingly valuable assets in healthcare firms, underscoring competitive pressure to secure specialized expertise. Technology innovators are propelling deal activity and strategic decision-making, while global pharmaceutical companies are strengthening their competitive position in the PE space, requiring PE sponsors to develop sophisticated strategies for competing and partnering with large-cap pharma actors.
The consensus among conference participants highlighted the necessity for PE firms to move beyond high-level strategy and boardroom guidance toward hands-on operational involvement, particularly in areas of talent management, compliance infrastructure, and technology integration. These findings establish critical parameters for how buyers and sellers should position healthcare transactions and portfolio company operations through 2026 and beyond.
A defining theme from the conference centers on a fundamental shift in how private equity firms create value in healthcare. A live poll conducted during HPE Miami panels revealed that operational execution ranked as the most significant determinant of near-term investment performance, surpassing financial engineering as the primary value driver. This finding reflects a broader evolution away from the traditional PE model of acquiring strong healthcare businesses and relying primarily on strategic boardroom guidance. Instead, institutional investors and PE sponsors increasingly expect firms to possess deep operational capabilities and specialized expertise embedded within portfolio companies, enabling active support for operational improvements rather than passive strategic oversight.
Compliance and quality assurance remain central to value creation in healthcare PE transactions, with panelists emphasizing these factors as non-negotiable components of deal structuring and post-acquisition performance. Panelists also identified talent retention and recruitment as increasingly valuable assets in healthcare firms, underscoring competitive pressure to secure specialized expertise. Technology innovators are propelling deal activity and strategic decision-making, while global pharmaceutical companies are strengthening their competitive position in the PE space, requiring PE sponsors to develop sophisticated strategies for competing and partnering with large-cap pharma actors.
The consensus among conference participants highlighted the necessity for PE firms to move beyond high-level strategy and boardroom guidance toward hands-on operational involvement, particularly in areas of talent management, compliance infrastructure, and technology integration. These findings establish critical parameters for how buyers and sellers should position healthcare transactions and portfolio company operations through 2026 and beyond.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.